ClinicalTrials.gg
CompletedNCT00200356Updated Oct 21, 2026Results posted

Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke

A Phase 4 interventional study of Edaravone and Sodium Ozagrel in Cerebral Infarction, sponsored by Shionogi. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Shionogi · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Aug 2004, registered Sep 2005).
Updated Oct 21, 2026Posted results revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
401
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.

02

Conditions studied

  • Cerebral Infarction

Browse trials for

03

In context

Cerebral Infarction

219 studies on the registry are indexed under Cerebral Infarction; 46 are open to participants now.

This study's enrollment of 401 is above the median of 120 across 139 interventional studies indexed under Cerebral Infarction.

Browse Cerebral Infarction studies →

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients can be receive drug treatment within 24 hours after stroke onset
  2. Patients with a level of consciousness between 0 (alert) and 3 (unable to recall name and date of birth) according to the Japan Coma Scale
  3. Patients with motor dysfunction of upper and/or lower extremities
  4. Patients aged 20 years or older when giving

Exclusion criteria

Exclusion Criteria:

  1. Serum creatinine of >1.5 mg/dL
  2. Embolic infarction
  3. Intracranial haemorrhage
  4. Large infarction with severe consciousness
  5. (TIA)
  6. A modified Rankin Scale score of ≥2 before stroke onset
  7. Patients were receive drug treatment (argatroban, urokinase, tissue plasminogen activator, heparin, warfarin sodium, aspirin, ticlopidine hydrochloride, cilostazol, edaravone and sodium ozagrel) after stroke onset
  8. Patients were receive surgical treatment or intravascular treatment
  9. With severe complications (cirrhosis, heart failure, etc.)
  10. Treating malignant tumor
  11. Pregnant or possibly pregnant women, nursing mothers
  12. History of edaravone, sodium ozagrel and ozagrel hydrochloride sensitivity
  13. Less than 3 months since any other clinical trial or postmarketing study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
401 participants (actual)

Study arms

  • Experimental
    Edaravone

    Drug: Edaravone

  • Active comparator
    Ozagrel

    Drug: Sodium Ozagrel

Interventions

  • Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening.

    Also known as: Radicut

  • Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening.

06

What researchers measure

Primary outcomes

  1. the Rate of Patients With a Modified Rankin Scale Score of 0-1

    The number of patients with mRS score of 0-1 (good outcome) at 3 months after treatment initiation. The mRS has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability.

    Time frame: 3 months

Secondary outcomes

  1. Barthel Index Score

    The Barthel Index of Activities of Daily Living measures functional disability by quantifying patient performance in 10 activities of daily life. These activities can be grouped according to self-care (feeding, grooming, bathing, dressing, bowel and bladder care, and toilet use) and mobility (ambulation, transfers, and stair climbing). 5-point increments are used in scoring, with a maximal score of 100 indicating that a patient is fully independent in physical functioning, and a lowest score of 0 representing a totally dependent bed-ridden state. The number of patients with 95-100 Barthel Index was evaluated at at 3 months after treatment initiation.

    Time frame: 3 months

  2. Baseline NIH Stroke Scale Score

    The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead).

    Time frame: Before treatment initiation

  3. NIH Stroke Scale Score at 14 Days

    The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 14 days after treatment initiation.

    Time frame: 14 days

  4. NIH Stroke Scale Score at 1 Month

    The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 1 month after treatment initiation.

    Time frame: 1 month

  5. NIH Stroke Scale Score at 3 Months

    The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 3 months after treatment initiation.

    Time frame: 3 months

  6. Japan Stroke Scale (Motor Function) Score at 14 Days

    The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 14 days after treatment initiation.

    Time frame: 14 days

  7. Japan Stroke Scale (Motor Function) Score at 1 Month

    The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 1 month after treatment initiation.

    Time frame: 1 month

  8. Japan Stroke Scale (Motor Function) Score at 3 Months

    The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 3 months after treatment initiation.

    Time frame: 3 months

  9. Modified Rankin Scale Score

    The number of patients with an Modified Rankin Scale score of 0-1 was evaluated at 6 months after treatment initiation. The Modified Rankin Scale has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability.

    Time frame: 6 months

07

Results

Posted Jan 15, 2013

Participant flow

Participant flow — Overall Study
MilestoneEdaravoneOzagrel
Started199202
Safety analysis set194198
Completed191195
Not completed87
Withdrew: Lack of efficacy33
Withdrew: Protocol violation44
Withdrew: Nontreatment10

Outcome measures

SecondaryBarthel Index Score

The Barthel Index of Activities of Daily Living measures functional disability by quantifying patient performance in 10 activities of daily life. These activities can be grouped according to self-care (feeding, grooming, bathing, dressing, bowel and bladder care, and toilet use) and mobility (ambulation, transfers, and stair climbing). 5-point increments are used in scoring, with a maximal score of 100 indicating that a patient is fully independent in physical functioning, and a lowest score of 0 representing a totally dependent bed-ridden state. The number of patients with 95-100 Barthel Index was evaluated at at 3 months after treatment initiation.

Time frame:
3 months
Reported as:
Number · participants
Barthel Index Score
participantsEdaravoneOzagrel
Barthel Index Score148133
SecondaryBaseline NIH Stroke Scale Score

The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead).

Time frame:
Before treatment initiation
Reported as:
Mean · scores on a scale
Baseline NIH Stroke Scale Score
scores on a scaleEdaravoneOzagrel
Baseline NIH Stroke Scale Score3.7 ± 2.33.8 ± 2.7
SecondaryNIH Stroke Scale Score at 14 Days

The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 14 days after treatment initiation.

Time frame:
14 days
Reported as:
Number · participants
NIH Stroke Scale Score at 14 Days
participantsEdaravoneOzagrel
NIH Stroke Scale Score at 14 Days98108
SecondaryNIH Stroke Scale Score at 1 Month

The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 1 month after treatment initiation.

Time frame:
1 month
Reported as:
Number · participants
NIH Stroke Scale Score at 1 Month
participantsEdaravoneOzagrel
NIH Stroke Scale Score at 1 Month117119
Primarythe Rate of Patients With a Modified Rankin Scale Score of 0-1

The number of patients with mRS score of 0-1 (good outcome) at 3 months after treatment initiation. The mRS has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability.

Time frame:
3 months
Reported as:
Number · participants
the Rate of Patients With a Modified Rankin Scale Score of 0-1
participantsEdaravoneOzagrel
Score(0-1)10998
04639
16359
23740
32229
41924
523
Death21
SecondaryNIH Stroke Scale Score at 3 Months

The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 3 months after treatment initiation.

Time frame:
3 months
Reported as:
Number · participants
NIH Stroke Scale Score at 3 Months
participantsEdaravoneOzagrel
NIH Stroke Scale Score at 3 Months135140
SecondaryJapan Stroke Scale (Motor Function) Score at 14 Days

The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 14 days after treatment initiation.

Time frame:
14 days
Reported as:
Mean · units on a scale
Japan Stroke Scale (Motor Function) Score at 14 Days
units on a scaleEdaravoneOzagrel
Japan Stroke Scale (Motor Function) Score at 14 Days4.521 ± 6.6514.686 ± 6.872
SecondaryJapan Stroke Scale (Motor Function) Score at 1 Month

The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 1 month after treatment initiation.

Time frame:
1 month
Reported as:
Mean · units on a scale
Japan Stroke Scale (Motor Function) Score at 1 Month
units on a scaleEdaravoneOzagrel
Japan Stroke Scale (Motor Function) Score at 1 Month3.632 ± 6.0863.680 ± 5.885
SecondaryJapan Stroke Scale (Motor Function) Score at 3 Months

The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 3 months after treatment initiation.

Time frame:
3 months
Reported as:
Mean · units on a scale
Japan Stroke Scale (Motor Function) Score at 3 Months
units on a scaleEdaravoneOzagrel
Japan Stroke Scale (Motor Function) Score at 3 Months2.507 ± 5.2322.927 ± 5.361
SecondaryModified Rankin Scale Score

The number of patients with an Modified Rankin Scale score of 0-1 was evaluated at 6 months after treatment initiation. The Modified Rankin Scale has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability.

Time frame:
6 months
Reported as:
Number · participants
Modified Rankin Scale Score
participantsEdaravoneOzagrel
Modified Rankin Scale Score112108

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Edaravone—27/194 (13.9%)102/194 (52.6%)
Ozagrel—28/198 (14.1%)107/198 (54%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventEdaravoneOzagrel
Cerebral infarctionNervous system disorders5/19411/198
IleusGastrointestinal disorders2/1940/198
PneumoniaInfections and infestations2/1941/198
Transient ischemic attackNervous system disorders2/1940/198
HemiplegiaNervous system disorders0/1942/198
Anastomotic ulcer haemorrhageInjury, poisoning and procedural complications1/1940/198
Angina pectorisCardiac disorders1/1940/198
Anti-neutrophil cytoplasmic antibody positive vasculitisImmune system disorders1/1940/198
ArrhythmiaCardiac disorders1/1940/198
AsthmaRespiratory, thoracic and mediastinal disorders1/1940/198
Most frequent other events
Most frequent other events
EventEdaravoneOzagrel
ConstipationGastrointestinal disorders59/19464/198
InsomniaPsychiatric disorders24/19433/198
NasopharyngitisInfections and infestations19/19413/198
Back painMusculoskeletal and connective tissue disorders11/19417/198
HeadacheNervous system disorders11/19412/198
Urinary tract infectionInfections and infestations9/19411/198
DiarrheaGastrointestinal disorders10/1946/198
PruritusSkin and subcutaneous tissue disorders9/19410/198

Baseline characteristics

Age, Customized
Age, Customized(years)EdaravoneOzagrelTotal
birth-19 years000
20-64 years6458122
65- years127137264
Sex: Female, Male
Sex: Female, Male(Participants)EdaravoneOzagrelTotal
Female7077147
Male121118239
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Shinohara Y, Saito I, Kobayashi S, Uchiyama S. Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). Cerebrovasc Dis. 2009;27(5):485-92. doi: 10.1159/000210190. Epub 2009 Mar 26. PubMed 19321945 ↗
10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2004 to primary completion in Oct 2006, 26 months.

Results were first posted in Jan 2013, 6 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 20, 2005
StartActual
Aug 31, 2004
Primary completionActual
Oct 31, 2006
CompletionActual
Oct 31, 2006
Results first posted
Jan 15, 2013
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 21, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionBarthel Index Score: how it is measured was reworded
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Posted results revised
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionBarthel Index Score: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT00200356
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Sep 20, 2005
Start date
Aug 31, 2004
Primary completion
Oct 31, 2006
Completion
Oct 31, 2006
Results posted
Jan 15, 2013
Last update
Oct 21, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion